Imetelstat Shows Promise for Myelodysplastic Syndromes

Menlo Park, Saturday, 14 June 2025.
Geron Corporation’s Imerge trial reveals that Imetelstat significantly improves quality of life and symptom management in lower-risk Myelodysplastic Syndrome patients, particularly enhancing hemoglobin levels in anemic cases.